<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00652873</url>
  </required_header>
  <id_info>
    <org_study_id>01211</org_study_id>
    <nct_id>NCT00652873</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fed Conditions</brief_title>
  <official_title>Randomized, 2-Way Crossover, Bioequivalence Study of Cabergoline 0.5 mg Tablets and Dostinex 0.5 mg Tablets Administered as 2 x 0.5 mg Tablets in Healthy Adult Females and Males Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Par Pharmaceutical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anapharm</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Par Pharmaceutical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the rate and extent of absorption of cabergoline 0.5 mg tablets (test) versus&#xD;
      Dostinex (reference)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the rate and extent of absorption of cabergoline 0.5 mg tablets (test) versus&#xD;
      Dostinex (reference) administered as 2 x 0.5 mg tablets under fed conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2001</start_date>
  <completion_date type="Actual">December 2001</completion_date>
  <primary_completion_date type="Actual">December 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and extent of absorption</measure>
    <time_frame>240 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>To Determine Bioequivalence Under Fed Conditions</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received the test product, Cabergoline 0.5 mg tablets under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received the reference product, Dostinex under fed conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabergoline</intervention_name>
    <description>Tablets 0.5 mg (2 x 0.5 mg dose), fed</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Dostinex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dostinex</intervention_name>
    <description>Tablets, 0.5 mg (2 X 0.5 mg dose), fed</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Cabergoline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects will be females or males, smokers or non-smokers&#xD;
&#xD;
          -  18 years of age and older&#xD;
&#xD;
          -  Subjects should read, sign and date an Informed Consent Form prior to any study&#xD;
             procedures&#xD;
&#xD;
          -  Subjects must complete all screening procedures within 28 days prior to the&#xD;
             administration of the study medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Breast feeding female subjects&#xD;
&#xD;
          -  Clinically significant anormalities found during medical screening&#xD;
&#xD;
          -  Any clinically significant gastrointestinal pathology or unresolved gastrointestinal&#xD;
             symptoms susceptible of interfering with the absorption of drugs&#xD;
&#xD;
          -  Clinically significant illnesses within 4 weeks of the administration of study&#xD;
             medication&#xD;
&#xD;
          -  Abnormal laboratory tests judged clinically significant&#xD;
&#xD;
          -  ECG abnormalities or vital sign abnormalities at screening&#xD;
&#xD;
          -  Subjects with BMI greater than or equal to 30.0&#xD;
&#xD;
          -  History of allergic reactions to cabergoline or ergot derivatives&#xD;
&#xD;
          -  Any food allergies, intolerances, restrictions, or special diet which in the opinion&#xD;
             of the medical subinvestigator, contraindicates the subject's participation in the&#xD;
             study&#xD;
&#xD;
          -  Positive urine drug screen at screening&#xD;
&#xD;
          -  Positive testing for hepatitis B, hepatitis C or HIV at screening&#xD;
&#xD;
          -  Positive urine pregnancy test at screening (performed on all females)&#xD;
&#xD;
          -  Use of investigational drug or participation in an investigational study, within 30&#xD;
             days prior to administration of the study medication&#xD;
&#xD;
          -  Donation of plasma (500 mL) within 7 days or donation or significant loss of whole&#xD;
             blood (450 mL) within 56 days prior to the administration of the study medication&#xD;
&#xD;
          -  History of significant alcohol abuse within six months of the screening visit or any&#xD;
             indication of the regular use of more than two units of alcohol per day&#xD;
&#xD;
          -  History of drug abuse or use of illegal drugs: use of soft drugs (marijuana, pot)&#xD;
             within 3 months of the screening visit or hard drugs (cocaine, PCP, crack)within 1&#xD;
             year of the screening visit&#xD;
&#xD;
          -  Subjects who have taken prescription medication within 14 days prior to administration&#xD;
             of study medication or over-the-counter products within 7 days prior to administration&#xD;
             of study medication, except for topical products without systemic absorption&#xD;
&#xD;
          -  Female subjects of childbearing potential who have had unprotected sexual intercourse&#xD;
             with any non-sterile male partner (i.e. male who has not been sterilized by vasectomy&#xD;
             for at last 6 months) within 14 days prior to the study drug administration. The&#xD;
             acceptable methods of contraception are condom + spermicide (at least 14 days prior to&#xD;
             study drug administration), diaphragm + spermicide (at least 14 days prior to study&#xD;
             drug administration)or intrauterine contraceptive device (placed at least 4 weeks&#xD;
             prior to study drug administration&#xD;
&#xD;
          -  Subjects who have taken any drugs known to induce or inhibit hepatic drug metabolism&#xD;
             within 30 days prior to administration of the study medication&#xD;
&#xD;
          -  Subjects who have undergone clinically significant surgery within 4 weeks prior to the&#xD;
             administration of the study medication&#xD;
&#xD;
          -  Any reason which, in the opinion of the medical subinvestigator, would prevent the&#xD;
             subject from participating in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Masson, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anapharm, Inc.</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>April 1, 2008</study_first_submitted>
  <study_first_submitted_qc>April 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2008</study_first_posted>
  <last_update_submitted>September 22, 2017</last_update_submitted>
  <last_update_submitted_qc>September 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <name_title>Alfred Elvin/Director of biopharmaceutics</name_title>
    <organization>Par Pharmaceutical, Inc.</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Cabergoline</keyword>
  <keyword>Fed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cabergoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

